Casgevy access in Pakistan: the DRAP named-patient pathway
How Pakistani families access Casgevy (exagamglogene autotemcel) for severe sickle cell disease and transfusion-dependent beta-thalassemia through the DRAP Special Permission route and qualified Authorized Treatment Centers abroad.
Last reviewed 2026-05-16 by Reserve Meds clinical and regulatory team.
Quick orientation
Casgevy (exagamglogene autotemcel) is the first CRISPR/Cas9 gene-edited cell therapy approved anywhere in the world, indicated by the US FDA for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT) in patients aged 12 and older. Pakistan carries one of the highest documented burdens of inherited hemoglobinopathies anywhere in the world: beta-thalassemia trait prevalence is estimated at 5 to 7 percent of the national population, and sickle cell disease is concentrated in Sindh and Balochistan, both patterns driven by autosomal recessive inheritance and Pakistan's elevated consanguinity rate. Casgevy is not registered with the Drug Regulatory Authority of Pakistan (DRAP), and no Pakistani institution currently holds Vertex Pharmaceuticals' Authorized Treatment Center (ATC) qualification, so access for Pakistani families is a travel-to-treatment engagement through the United States, the United Kingdom, the European Union, or Saudi Arabia. Reserve Meds coordinates the destination-center introduction, the documentation kit, and the multi-country family funding workflow.
Reserved for you.
Why Pakistan patients need Casgevy through the named-patient pathway
The thalassemia and sickle cell burden in Pakistan is structural rather than incidental. Beta-thalassemia carrier rates of 5 to 7 percent translate into roughly 5,000 to 9,000 transfusion-dependent children identified each year, and the prevalence of SCD among Sindhi, Baloch, and Makrani populations is well-documented in the published Pakistani hematology literature. Families typically navigate lifelong red cell transfusion programs, iron chelation with deferasirox or deferiprone, and the steady accumulation of transfusion-related complications: iron overload, alloimmunization, splenomegaly, and cumulative end-organ damage. For adolescents and young adults with severe phenotypes, the case for a one-time potentially disease-modifying gene therapy is clinically compelling.
The access gap for Casgevy in Pakistan is not a "registered but unstocked" problem. It is a deeper structural gap with four distinct layers. First, regulatory: Casgevy has not been filed with DRAP for marketing authorization. Second, infrastructural: the certified Authorized Treatment Center network that Vertex Pharmaceuticals qualifies for cell-therapy delivery does not include any Pakistani institution. Third, technical: the cryogenic vapor-phase liquid nitrogen handling, busulfan myeloablative conditioning experience at the per-protocol intensity, dedicated cell-therapy infusion suite, and post-engraftment ICU-grade transfusion and antimicrobial support that the protocol demands sit at scale only at a small global set of academic centers. Fourth, payer: there is no Pakistani insurance product or government scheme that reimburses a multi-million-dollar one-time gene therapy at list. Aga Khan University Hospital (AKUH) and Shaukat Khanum Memorial Cancer Hospital and Research Centre (SKMCH&RC) operate respected bone marrow transplant programs, but neither holds Vertex's Casgevy ATC qualification at this time.
The practical access route, therefore, is cross-border travel-to-treatment. The patient and family travel to a qualified center in the United States, the United Kingdom, the European Union, or Saudi Arabia, where Casgevy is registered and where the institutional infrastructure exists. Reserve Meds orchestrates the introductions, the documentation, and the supply-side coordination across what is typically a multi-city, multi-country case.
The DRAP named-patient pathway for Casgevy
DRAP regulates the import of medicines through the Quality Assurance and Laboratory Testing (QA<) Division's Import and Export Section, with the Drug Registration Board overseeing new product registration. For unregistered medicines required for a specific patient, DRAP issues a Special Permission, also called the No Objection Certificate (NOC) for Personal Use Import, filed through the Online Import and Export System (OIES) portal at www.dra.gov.pk. For most named-patient drug imports into Pakistan, this is the relevant pathway, and the legal foundation is the Drugs Act 1976 and the DRAP Act 2012.
For Casgevy specifically, the DRAP filing typically does not target the cell product itself, because the manufactured edited cells are returned directly to the patient at the treating center abroad rather than imported as a stand-alone pharmaceutical into Pakistan. Where the DRAP pathway becomes relevant is for ancillary medicines used in post-engraftment care, for return-to-Pakistan follow-up medicines, or where a Pakistani patient is treated abroad and continues post-engraftment monitoring at home. The dominant access architecture is travel-to-treatment, with the primary regulatory layer concentrated at the destination jurisdiction (FDA for the US, MHRA for the UK, EMA for the EU, SFDA for Saudi Arabia).
Where the Pakistan-side documentation matters most is patient and family preparation for the destination institution's intake review. A complete file includes a clinical justification letter from the treating Pakistani hematologist confirming diagnosis with ICD-10 coding (D57.x for SCD or D56.x for TDT), severity with documented vaso-occlusive crisis history or transfusion dependence, prior therapies attempted (hydroxyurea, voxelotor where available, chronic transfusion, iron chelation) with outcomes, and the clinical rationale for one-time gene-edited cell therapy; Pakistan Medical and Dental Council (PMDC) licensing verification of the prescribing physician; a recent organ function workup (cardiac, hepatic, pulmonary); HLA typing where relevant; a fertility preservation discussion record; and family logistics planning that the destination institution's case manager will request.
Regulatory timelines for any DRAP-side filing for routine cases at a major institution run four to eight weeks; complex cases extend to ten to sixteen weeks. The operational clinical timeline at the destination institution (apheresis through manufacturing through conditioning through engraftment) is six months to one year. Mandatory pre-treatment fertility preservation counseling is documented as part of the patient's pre-engagement education at the destination center; the busulfan conditioning regimen carries a high risk of permanent infertility, and the fertility discussion is not optional under any qualified ATC's protocol.
Where Casgevy gets dispensed for Pakistani patients
Within Pakistan, the institutions that handle international referrals and pre- and post-treatment workup most fluently are concentrated in Karachi, Lahore, and Islamabad. Aga Khan University Hospital (AKUH) in Karachi, with its JCI-accredited hematology service and established BMT program, is the most common entry point for Casgevy candidacy assessment. Shaukat Khanum Memorial Cancer Hospital and Research Centre (SKMCH&RC) in Lahore and Peshawar operates a high-volume pediatric and adult oncology and BMT footprint and routinely produces the kind of comprehensive workup that destination institutions require. The Indus Hospital and Health Network in Karachi treats a large pediatric thalassemia cohort and is a frequent originator of cell-therapy referrals.
Other institutions that participate in the international referral pattern include Liaquat National Hospital in Karachi, the Pakistan Kidney and Liver Institute (PKLI) in Lahore, the Combined Military Hospitals (CMH) network for military families, the Children's Hospital and Institute of Child Health (CH&ICH) in Lahore for pediatric cases, and Shifa International Hospital in Islamabad. Quaid-e-Azam International Hospital in Islamabad and Hashmanis Hospital in Karachi also feed the international hematology referral stream.
The actual Casgevy delivery takes place at the destination institution abroad. Vertex's qualified Authorized Treatment Center network includes US academic medical centers (Boston Children's Hospital, Memorial Sloan Kettering, City of Hope, Sarah Cannon Research Institute at TriStar Centennial, Children's National in Washington DC, Cleveland Clinic, and others), UK NHS designated centers (Manchester, Royal Marsden, King's College Hospital London for adult sickle cell), EU centers in Italy (Ospedale San Raffaele Milan) and Germany among others, and in Saudi Arabia primarily King Faisal Specialist Hospital and Research Centre (KFSH&RC) Riyadh and Jeddah. For Pakistani families with relatives in the Gulf, Saudi Arabia is often the closest qualified destination and the most operationally practical, including for language and cultural fit and visa logistics. For families pursuing the US route, the B1/B2 visa process plus the six-month-plus treatment stay become part of the planning conversation.
Real cost picture for Casgevy for Pakistani families
The Casgevy cost structure is dominated by the manufactured cell product itself. US wholesale acquisition cost (WAC) is approximately USD 2.2 million per patient for the single one-time infusion (Vertex stated list price at launch, widely reported). At the current USD to PKR rate (approximately 1 USD = 280 PKR in May 2026), the cell product alone converts to roughly PKR 616 million. This figure covers the cell product only. It does not include apheresis, manufacturing logistics, busulfan conditioning hospitalization, the cell-therapy infusion suite, post-infusion inpatient stay with transfusion and antimicrobial support, fertility preservation, or long-term follow-up.
All-in delivered cost at a qualified destination center is materially higher than the cell-product WAC. Typical destination-center quotes for the full treatment arc (workup, apheresis, manufacturing, conditioning, infusion, engraftment recovery, year-1 follow-up) range from USD 2.6 million to USD 3.4 million depending on destination jurisdiction, length of inpatient stay, and complication profile. International logistics for the manufactured cell product (cryogenic vapor-phase liquid nitrogen shippers) are absorbed within the treating institution's commercial arrangement with Vertex and do not become a separate line item for the family. Patient and caregiver travel costs (visa, international airfare, multi-month accommodation near the destination institution, in-country transport, food) add USD 60,000 to USD 180,000 depending on destination, family configuration, and length of stay. The Reserve Meds concierge coordination fee is a separate transparent line item on every firm quote.
Because the Pakistani Rupee has been volatile and headline inflation remains elevated in 2026, Reserve Meds quotes in USD and accepts wire transfers from any USD-accessible source. Pakistani families regularly pool funding across overseas relatives in Saudi Arabia, the UAE, the UK, North America, and Australia; the single-coordinator model is built specifically for this multi-currency, multi-relative funding pattern. No Pakistani private insurer (Adamjee, EFU, Jubilee, IGI, TPL, State Life) reimburses a multi-million-dollar one-time gene therapy. The State Bank of Pakistan's annual medical-treatment outward remittance allowance is constrained relative to Casgevy's cost; in practice, funding flows from overseas family members directly to the destination institution. We do not promise insurance or government scheme coverage from any source.
Typical timeline for Casgevy for Pakistani patients
From the date a Pakistani family decides to pursue Casgevy seriously, the overall arc runs roughly nine to fifteen months. The first four to eight weeks are workup and documentation in Pakistan: complete clinical justification, organ function workup, infection screening, HLA typing where relevant, fertility preservation discussion, family logistics planning. The next four to eight weeks are destination-center intake review, visa coordination where applicable (B1/B2 for the US can take 8 to 20 weeks in 2026 for Pakistani applicants depending on consular post; UK is generally faster), and Vertex manufacturing-slot allocation.
The active treatment arc itself runs six months to one year: pre-apheresis mobilization with plerixafor and filgrastim, apheresis collection of CD34+ stem cells, cryopreserved shipment to the Vertex manufacturing facility, multi-week edit-and-expansion manufacturing, return shipment of the edited product to the treating center, busulfan myeloablative conditioning, infusion, profound cytopenia and engraftment recovery (typically 30 to 60 days inpatient), and the structured outpatient follow-up window. Long-term follow-up extends multiple years through the Vertex post-marketing registry. There are no shortcuts on this timeline. The biology of mobilization, manufacturing, and engraftment sets the pace, and the regulator is rarely the rate-limiting step.
What your physician needs to provide
The clinical justification letter is the cornerstone of any Casgevy case file involving a Pakistani patient. The letter, signed by a treating hematologist holding an active PMDC registration number with appropriate provincial medical council registration where required, addresses the patient's diagnosis with ICD-10 coding (D57.x for SCD or D56.x for TDT), disease severity (documented vaso-occlusive crisis history for SCD, including hospitalization count and acute chest syndrome episodes; or transfusion frequency, ferritin trajectory, and iron-overload markers including liver and cardiac T2* MRI where available for TDT), prior therapies attempted (hydroxyurea dose and duration, voxelotor where available, chronic transfusion program detail, iron chelation regimen with deferasirox or deferiprone) with outcomes, and the clinical case for one-time gene-edited cell therapy.
The dosing reference is the FDA label minimum of 3 x 10^6 CD34+ cells per kilogram of body weight, delivered as a single intravenous infusion of the patient's own edited autologous CD34+ product. The monitoring plan covers the pre-apheresis baseline workup (bone marrow assessment, infection screen including HIV, hepatitis B and C, CMV, and tuberculosis given Pakistani epidemiology, organ function evaluation with cardiac echocardiogram and pulmonary function, fertility preservation discussion), the inpatient myeloablative conditioning window, the profound cytopenia and engraftment recovery period with transfusion and antimicrobial support, and the long-term hematologic and safety follow-up per the Vertex registry.
The mandatory pre-treatment fertility preservation discussion is documented as a discrete element of the file, not buried in the broader narrative. The receiving treating institution abroad will not initiate the apheresis-to-conditioning arc without a documented fertility preservation discussion completed. Pakistan's regulatory pharmacovigilance framework operates through DRAP's Pharmacovigilance Cell within the Health Services Division; adverse event reporting obligations for any imported ancillary materials remain with the prescribing physician and the institution. Tuberculosis screening is treated as routine, not optional, given the country-level epidemiology.
Common questions about Casgevy in Pakistan
Can Casgevy be administered in Pakistan? Not at this time. No Pakistani institution holds Vertex's Authorized Treatment Center qualification, and the manufacturing and infusion infrastructure required is concentrated at a small global set of academic centers. AKUH and SKMCH&RC operate strong BMT programs, but neither holds Casgevy ATC status. The practical access route is travel-to-treatment to a qualified ATC in the US, UK, EU, or Saudi Arabia.
Will Adamjee, EFU, Jubilee, IGI, TPL, or State Life cover this? No Pakistani private insurer reimburses a multi-million-dollar one-time gene therapy as a standard line item. Federal Government Employees Health Insurance and provincial health card schemes (Sehat Sahulat Card) do not cover unregistered international gene therapies at this price point. Cash-pay funded through overseas family wires is the default operating posture. We provide documentation that lets any payer assess; the claim itself sits with you.
Which destination is the best fit for a Pakistani family? The clinical decision rests with the treating cell-therapy team after intake review, but operationally three patterns are common. Saudi Arabia (KFSH&RC Riyadh or Jeddah) is the closest qualified destination, often the strongest fit for language, cultural alignment, and Pakistani diaspora support; the SFDA Special Access Pathway is well-established and the visa logistics for Pakistani nationals are generally straightforward. The UK (Manchester, Royal Marsden, King's College Hospital London) is the historical second choice given Pakistani-British family networks. The US route is highest-cost and slowest on the visa side but offers the deepest ATC bench. The EU (Milan, German centers) is used selectively.
Is fertility preservation really mandatory? Yes. The busulfan conditioning regimen carries a high risk of permanent infertility, and the fertility preservation discussion is part of pre-treatment eligibility at every qualified treating center. Sperm or oocyte cryopreservation pathways exist at AKUH and at major Lahore IVF centers; the destination ATC's reproductive endocrinology service handles the post-arrival side. The discussion happens before conditioning begins, not after.
Why Casgevy versus Lyfgenia for our case? Casgevy uses CRISPR-Cas9 to edit the BCL11A enhancer and reactivate fetal hemoglobin. Lyfgenia uses a lentiviral vector to add a modified beta-globin gene and carries an FDA boxed warning for hematologic malignancy that Casgevy does not. Casgevy is also approved for transfusion-dependent beta-thalassemia, which is materially high-prevalence in Pakistan; Lyfgenia is not approved for TDT. Casgevy carries broader international registration (UK MHRA, EU EMA, SFDA), which matters operationally for Pakistani families travelling for treatment. The clinical choice rests with the treating cell-therapy team.
Is this a legitimate alternative to crowdfunding? Yes. Reserve Meds is a US-based concierge coordinator with documented sourcing, documented chain of custody, single-coordinator continuity, and transparent line-item pricing. The architecture is built specifically for the Pakistani family pattern of cross-border coordination across Karachi, Lahore, Riyadh, London, Dubai, and Toronto, as a documented alternative to ad-hoc arrangements that have characterized Pakistani international gene-therapy funding in the past.
How does the funding flow work in practice? Funds wire from one or more overseas family members directly to the destination institution's patient account, with milestone-tagged tranches at workup acceptance, apheresis, manufacturing slot confirmation, conditioning admission, and infusion. The Reserve Meds concierge fee is wired separately to Reserve Meds in the US. We do not handle drug cost wires through Reserve Meds accounts; the family pays the destination institution and Vertex through the institution's standard channels.
Where Reserve Meds fits in Casgevy cases for Pakistan
Reserve Meds is a US-based concierge coordinator. For a Casgevy inquiry from a Pakistani family, the working unit is qualified Authorized Treatment Center introduction, US-side or destination-side coordination on manufacturing slot scheduling, documentation kit preparation for the Pakistan-side file (clinical justification, PMDC verification, DRAP reference for ancillary materials where applicable, fertility preservation record, family logistics plan), and continuous coordination through the multi-month treatment arc and into long-term follow-up. The clinical decisions remain with the treating hematology and cell-therapy team. The regulatory authority remains DRAP on the Pakistan side and the corresponding authority on the destination side (SFDA, FDA, MHRA, EMA). The cell-therapy delivery remains with the qualified treating center.
What Reserve Meds carries: identification of the qualified treating institution with manufacturing slot availability, preparation of the documentation kit including the mandatory fertility preservation discussion reference, coordination of cryogenic shipment logistics from the Vertex manufacturing site to the treating center, multi-city family coordination across Pakistan and the destination country, multi-currency funding workflow with overseas family wires, and a single named coordinator who stays with the family through apheresis, manufacturing, conditioning, infusion, and the long-term follow-up window for ancillary materials. DSCSA chain-of-custody documentation applies wherever the US procurement leg touches the case.
Next step
If your family is considering Casgevy for severe sickle cell disease or transfusion-dependent beta-thalassemia, the first step is a coordinated intake that confirms eligibility, identifies the appropriate destination ATC, and produces a transparent firm quote. The waitlist request prefills the relevant context so the coordinator who reaches out is already oriented to your case.
Reserved for you.